• Fyllo

  Participated · Series C · Nov 2021

  Chicago-based Fyllo, led by founder and CEO Chad Bronstein, delivers the Compliance Cloud, a suite of software and services that simplifies regulatory management for companies operating in tightly controlled sectors like cannabis. Its offering combines compliance monitoring, data services and marketing tools, and is complemented by the Fyllo Data Marketplace, which lets mainstream advertisers target cannabis and CBD consumers. The company is expanding its capabilities through M&A, including the February 2021 acquisition of retail and marketing platform DataOwl. Fyllo plans to continue strategic acquisitions and aggressive hiring to bolster its technology stack. Year-to-date in 2021 the business has grown revenue more than 100% and expanded headcount by roughly 275%, adding executives from firms such as Twitter and Salesforce. These metrics underscore rising demand for compliance-first SaaS in regulated markets, positioning Fyllo for continued growth.

• Kadenwood

  Participated · Series B · Jul 2021

  Kadenwood sells vertically integrated, hemp-derived CBD consumer packaged goods across major drug and grocery chains, with brands including LEVEL SELECT™, Purity Preferred™ Pet CBD and Purity Organic™ CBD Teas. Led by co-founder and CEO Erick Dickens, the company operates as a supplier and manufacturer following its acquisition of EcoGen Biosciences. In the first half of 2021 Kadenwood expanded via acquisitions such as Healist Advanced Naturals and Social CBD to broaden retail and e-commerce distribution and mass-market offerings. The company intends to use new capital to accelerate scale, pursue strategic partnerships and execute further acquisitions. The business emphasizes vertical integration across manufacturing and branded CPG to support retail expansion. No revenue or user metrics were disclosed in the article.

• Front Range Biosciences

  Participated · Equity · Sep 2019

  Front Range Biosciences specializes in next-generation plant breeding, plant tissue culture, and cannabis seed development to improve the reliability and quality of industrial hemp and medical cannabis genetics. The company runs a Clean Stock program that supplies disease- and pathogen-free plants and seeds backed by data-driven breeding solutions. FRB operates facilities in Colorado, California and Wisconsin and maintains a partnership with the Center for Research in Agricultural Genomics in Barcelona, Spain, giving it global reach. Founded in 2015 and headquartered in Lafayette, Colorado, the company positions itself as a market-leading R&D program in hemp and cannabis genetics. FRB is currently raising a $30M Series B financing round and has attracted investment from KEY Investment Partners, which will act as a strategic partner. KEY founding partner Pete Karabas is joining Front Range Biosciences' board as a board observer. Front Range Biosciences is a Lafayette, Colorado–based agricultural biotech that provides technology for breeding and producing new plant varieties and seeds in hemp, coffee and regulated cannabis. The company raised $8.5M in funding to support continued expansion of its hemp and cannabis portfolio. FRB plans to expand hemp seed production both nationally and globally and scale its young plant program, with production capabilities expected to multiply in 2020. Led by CEO and Co‑Founder Jon Vaught, the company has operated for a little more than three years. During that time FRB built over 160,000 square feet of facilities across Colorado, California and Wisconsin, acquired a cannabis genomics team and shipped millions of plants to farmers and growers nationwide. The new funds are intended to accelerate those production and portfolio expansion efforts. Front Range Biosciences develops Clean Stock® plant material using tissue culture, a sterile propagation technique, to address disease, inefficiency, inconsistency and scale for high-value crops. Its core product is sterile, duplicated baby plants on a defined nutrient medium for crops such as hemp, cannabis and coffee. The company supplies Clean Stock to growers and has partnerships to expand production, including with Frinj Coffee for coffee cuttings and Faith and Family Farms for cannabis in California. Led by CEO and co-founder Dr. Jonathan Vaught, Front Range is expanding Clean Stock production into California and taking orders for late 2018. It plans to use new funding to accelerate its Clean Stock program across Colorado, California and Canada, pursue IP development, and resource its varietal development program for hemp and cannabis. Front Range Biosciences specializes in tissue culture propagation of high-value crops, aiming to resolve cultivators' operational problems such as disease, inefficiency, inconsistency and limited scale. The company runs a varietal improvement program that leverages sequencing technology to map cannabis genetics and develop commercially relevant traits, including disease resistance, oil and resin yield, and desirable cannabinoid profiles. Front Range is led by CEO and co-founder Dr. Jon Vaught and COO and co-founder Nick Hofmeister. The company intends to use recent funding to scale its processes and expand into California and other legal cannabis states in the U.S. Its core product and R&D focus combine propagation services with genetic improvement to deliver more reliable, higher-yielding plant varieties for cultivators. Front Range Biosciences offers industrial-scale tissue culture propagation and an advanced breeding platform aimed at improving cannabis clone consistency and commercial traits. Its flagship product is tissue culture propagation for scalable, consistent clone production. The company also develops breeding tools to identify and enhance commercially relevant traits. Front Range will use new funding to build out its team and expand its tissue culture offering to improve efficiency and consistency for clone production. The company participated in the CanopyBoulder accelerator program for cannabis startups last year. It recently closed a $1.5 million seed round to support these efforts.

• Enlighten

  Participated · Series B · Jun 2019

  Enlighten is a multifaceted cannabis technology company that provides a media and adtech platform reaching cannabis consumers. Based in Bowling Green, Kentucky, the company serves nearly 1,000 cannabis and hemp businesses, including dispensaries, cultivators and producers, head shops, cannabis lounges and healthcare facilities. Led by Chairman and CEO Jeremy Jacobs, Enlighten positions itself as a full-scale enterprise technology solution for the cannabis industry. The company intends to use the Series B proceeds to further expand its TV network, finalize new technology and data solutions, and expand its wellness division focused on alternative health. Financially, the company closed an over $6.5 million Series B round. Investors in the round included Tuatara Capital, L.P. as lead and participation from Arcadian New Venture Fund, L.P. Eyechronic operates an ad-based television network that broadcasts real-time content on large screens placed in legal cannabis dispensaries across the U.S. The network runs social media walls, trivia, weekly educational segments and recent news to engage customers, increase revenue, and raise brand awareness. The company sells marketing services to dispensaries and cannabis brands and designs content to maximize effectiveness at point of sale. Eyechronic is led by co-founder and CEO Jeremy Jacobs. It raised $3M in a Series A that brings total capital raised to $5.25M. The new funding is intended to enable expansion into new markets, including California after that state’s adult-use launch on January 1, 2018.

• KelSie Biotech

  Participated · Series A · May 2019

  KelSie Biotech develops high-bioavailability delivery methods for active pharmaceutical ingredients across medical, nutraceutical and CBD/cannabis fields. The company licenses patented and proprietary technologies based on novel particle morphology science. Its technology portfolio includes dry-inhaled powder and true sublingual delivery systems. The dry-inhaled powder technology completed Phase I clinical trials for delivery of a stable measles vaccine. Led by Cameron Keluche and based in Boulder, CO, KelSie pursues a licensing business model for its delivery platforms. The company said it will use newly raised funds to support scientific research and market expansion.

No current team members are available.